Join us for presentations using MRDR data and visit the Monash University booth - Booth 12. We'd love to chat about the registry, answer any questions or simply come say hi!
|
Presenter |
Project |
Oral/ Poster |
Title |
Theme |
Board Number |
Oral Time |
Session |
|
Georgia McCaughan/Betty Gration |
ANZ MRDR |
Oral |
Presence of end organ damage at commencement of second line therapy significantly impacts outcomes in Multiple Myeloma: An Australia and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR) Analysis |
HSANZ - Myeloma
|
|
Mon, Oct 19, 8:45AM – 9:00AM |
HSANZ Free Communications: Myeloma
|
|
Jeremy Hu/ Ken Lim |
ANZ MRDR |
Oral |
Real-world application of the IMS/IMWG consensus genomic staging criteria for high-risk multiple myeloma: a report from the Australia and New Zealand Myeloma and Related Diseases Registry |
HSANZ - Myeloma
|
|
Mon, Oct 19, 11:30AM – 11:45AM |
HSANZ Presidential Symposium |
|
Adam Irving |
ANZ MRDR |
Poster |
Valuing new treatments before market entry: Calibrated Transport of trial evidence |
HSANZ - Myeloma
|
Board HP167 |
|
HSANZ - Myeloma
|
|
Elizabeth Moore |
ANZ MRDR |
Poster |
More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial |
HSANZ - Myeloma
|
Board HP241 |
|
HSANZ – Supportive Care |